Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the FDA and is currently marketed in various dosage strengths and forms as Mounjaro and Zepbound
For comparison, weight-loss figures reported in the major semaglutide and tirzepatide trials were lower, which is why Retatrutide is often described as the most powerful candidate seen so far
The American College of Physicians recommends adding either an SGLT2 inhibitor or a GLP-1 agonist to metformin when blood sugar control is insufficient, allowing for a more tailored treatment approach
2 Methods 2.1 Clinical Study Design and Participants This was a single centre (Profil, Neuss, Germany), randomised, double-blind, three-period crossover study (Fig
First, this study was retrospective in nature and was based on EMR data
Contraindications include active cancer, severe retinopathy, recent cardiac events, and uncontrolled diabetes